Elabela/toddler: New peptide with a promising future in cancer diagnostic and therapy.

Biochim Biophys Acta Mol Cell Res

Institut National de la Santé et de la Recherche Médicale U1029 LAMC, F-33400 Talence, France; Université de Bordeaux F-33400, Talence, France. Electronic address:

Published: August 2021

Elabela/toddler is the second endogenous ligand recently identified after Apelin, that binds to the G protein-coupled receptor APJ. Elabela is a 54-amino acid peptide initially identified in fish and human genomes and classified as noncoding. This precursor can be cleaved to shorter sequences (32, 21, and 11 amino acids), which bind and activate APJ, and can be blocked by APJ antagonists. Contrary to Apelin and APJ, widely distributed in organs and tissues, Elabela expression is more restricted, and different studies have revealed the potential role of Elabela in cancers. This review summarizes the current studies focusing on the role of Elabela in different cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbamcr.2021.119065DOI Listing

Publication Analysis

Top Keywords

role elabela
8
elabela cancers
8
elabela/toddler peptide
4
peptide promising
4
promising future
4
future cancer
4
cancer diagnostic
4
diagnostic therapy
4
therapy elabela/toddler
4
elabela/toddler second
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!